Author: admin
Out of thousands of recipes, these dinner, lunch, breakfast, snack and drink recipes are the most popular EatingWell dishes of 2025. From our High-Protein Blueberry & Peanut Butter Chia Pudding with nearly 9,000 saves, to our Weight Loss Cabbage Soup with almost 50 5-star reviews, these recipes are the best of the best. Try one (or all) of these popular recipes and see if they’re worth the hype. Love these recipes? Join MyRecipes to save them all with one click. It’s so easy—and free! High-Protein Blueberry & Peanut Butter Chia Pudding Photographer: Jen Causey; Food Stylist: Chelsea Zimmer; Prop Stylist:…
Nature, Published online: 01 December 2025; doi:10.1038/d41586-025-03805-yTwo studies suggest that T cells with stem-cell-like properties could work with antibody therapies to control HIV after a person stops taking antiviral pills.
Support strong strands from within.*
Recall issued for Your Fresh Market Broccoli Florets due to Salmonella risk.Affected bags were sold in retail locations in six Canadian provinces.Dispose recalled broccoli and contact a healthcare professional if you’re experiencing symptoms. There’s an active recall on broccoli florets sold across Canada, according to the Canadian Food Inspection Agency (CFIA). This is due to a Salmonella contamination. The recall is impacting Your Fresh Market Broccoli Florets sold in 907-gram plastic bags. The packaging sports UPC “6 27735 27054 8,” best-by date November 26, 2025, and lot code “25318.” The broccoli was sold at retail and grocery stores in the…
As consumer interest in wellness, healthy aging, and performance nutrition continues to grow, ingredient suppliers are adjusting their portfolios and development strategies to meet new demands. Addressing this, Ingredients + Specialties from Univar Solutions is innovating around GLP-1-related dietary changes, rising expectations around protein quality and functionality, and increasing attention to sustainability in formulation.The company also spotlights recent investments in new food kitchens and solution centers around the globe, aimed at expanding technical support and accelerating product development for brand partners.In conversation with Sarah Gonçalves, senior business development manager for Nutraceuticals at Ingredients + Specialties from Univar Solutions, Nutrition Insight…
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January 1st. In the 18 months since Khan joined Recursion leadership, the Salt Lake City-based company completed its combination with Exscientia, one of the largest M&A events in the AI drug discovery field, followed by workforce reductions and pipeline pruning in 2025. Gibson, who will transition to board chair, stated that Recursion is seeking a leader with a different skillset as the company moves to later-stage clinical programs. At the core of…
In a landmark decision that will reshape how we approach obesity treatment worldwide, the World Health Organization1 has released its first-ever clinical guidelines recommending GLP-1 therapies for adults living with obesity. This isn’t merely another drug approval or incremental policy update; it represents a transformation in how the world’s leading health authority understands and addresses a condition affecting over 1 billion people globally.
Image credit:The ScientistThe Top Innovations contest is a yearly staple for The Scientist that showcases the most transformative and useful advances in life science techniques and products. Our contest nominees continuously prove how rich the life science innovation landscape has become. For the first time this year, we introduced four distinct categories–Biotechnology, Lab Research Tools, Healthcare and Diagnostics, and Emerging Startup Technologies—expanding the spotlight on innovation across the life sciences. In this two-part Shaping Science episode, the 2025 Top Innovations winners introduce their technologies and highlight how they are driving research and healthcare forward.For more information on these innovations, including…
Voyxact gets accelerated approval, offering investors a new entrant in the high-value kidney disease market. The Food and Drug Administration (FDA) has granted accelerated approval to Otsuka Pharmaceutical’s Voyxact, the first therapy in an emerging class of medicines targeting the autoimmune kidney condition IgA nephropathy (IgAN) [1]. The decision positions Otsuka at the front of a rapidly expanding market, one that analysts estimate could be worth between $6 billion and $10 billion in the US alone. IgAN, also known as Berger’s disease, is caused by a buildup of abnormal antibodies in the kidneys. These antibodies trigger inflammation and leave the…
Nature, Published online: 01 December 2025; doi:10.1038/d41586-025-03878-9A specially trained algorithm could aid the search for biological activity both on the early Earth and on other worlds.